Results 81 to 90 of about 7,425 (188)

When can we stop cabergoline treatment in prolactinomas?

, 2003
Prolactinoma is the most common hormone-secreting pituitary adenoma. The approach to prolactinomas has changed in the past 25 years, thanks to treatment with dopamine agonists, which is characterized by a potent prolactin inhibitory effect, a tumor ...
A. Colao, G. Vitale, A. Di Sarno, G. Lombardi, F. Rota   +4 more
core   +1 more source

Profile of leptin, adiponectin, and body fat in patients with hyperprolactinemia: Response to treatment with cabergoline

Indian Journal of Endocrinology and Metabolism, 2016
Introduction: Though hypoadiponectinemia and leptin resistance have been proposed as potential factors for weight gain in patients with hyperprolactinemia (HPL), the effects of HPL and cabergoline on these adipocyte-derived hormones are not clear.
Nazir Ahmad Pala, Bashir Ahmad Laway, Raiz Ahmad Misgar, Zaffar Amin Shah, Tariq A Gojwari, Tariq A Dar   +5 more
doaj   +1 more source

Growth hormone deficiency, secondary hypothyroidism, and empty sella following treatment of childhood macroprolactinoma

Indian Journal of Endocrinology and Metabolism, 2013
Macroprolactinoma are rare in childhood, especially in the first decade. A 9-year-old girl presented with headache, vomiting, and decreased vision for 8 months. A diagnosis of macroprolactinoma was made following documentation of elevated serum prolactin
Chitra Selvan, Deep Dutta, Sujoy Ghosh, Satinath Mukhopadhyay, Subhankar Chowdhury   +4 more
doaj   +1 more source

Cabergoline monotherapy in the long-term treatment of Cushing's disease

, 2010
BackgroundCabergoline is a long-acting dopamine receptor agonist used to treat prolactinomas. Identification of D2 receptors in corticotroph tumors led to clinical trials of cabergoline therapy in limited cases of Nelson's syndrome, ectopic ACTH ...
Hugues Beauregard, Marcos Manavela, André Lacroix, Karina Danilowicz, Oscar Domingo Bruno, Ariane Godbout   +5 more
core   +1 more source

ACTH silent adenoma shrinking under cabergoline. [PDF]

, 2001
peer reviewedOBJECTIVES: The authors present a case report that proposes the use of cabergoline treatment in silent ACTH adenoma, an unusual member of the heterogeneous group of the so-called clinically non-functioning pituitary adenomas.
Petrossians, Patrick, Kalife, A., Stevenaert, Achille, Tabarin, A., Valdes Socin, Hernan Gonzalo, Ronci, N., Bloch, B., Beckers, Albert   +7 more
core   +1 more source

Giant prolactinoma case with side effects due to cabergoline

, 2020
Dopamine agonists should usually be the first treatment for patients with prolactinomas of all sizes, because these drugs decrease serum prolactin concentrations and decrease the size of most lactotroph adenomas. Cabergoline is preferred first.
Hüseyin Dursun, Ali Kurtsoy, Semiha Çalkaya*, Fahri Bayram   +3 more
core   +1 more source

Cabergoline for migraine prevention (PROTECT): Protocol for a randomized, placebo-controlled, double-blind trial

Cephalalgia Reports
Cabergoline, a dopamine receptor agonist, has shown beneficial effects as a preventive treatment for migraine, with no serious adverse events reported.
Astrid Johannesson Hjelholt, Kristina Laugesen, Randi Maria Hanghøj Tei, Helge Kasch, Hans-Christoph Diener, Jens Otto Lunde Jørgensen   +5 more
doaj   +1 more source

Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly

, 2010
Cabergoline, an ergot-derived dopamine receptor agonist, is used widely in the treatment of Parkinson's disease (PD) and hyperprolactinemia, but may cause heart valve fibrosis, retraction, and clinically significant regurgitation in PD patients.
Izgi, Cemil, Cevik, Cihan, Feray, Hasan, Nugent, Kenneth, Saltan, Yelda, MANSUROĞLU, DENYAN   +5 more
core  

Effectiveness of Cabergoline therapy in hyperprolactinemic infertility [PDF]

, 2019
Background: Hyperprolactinemia may be associated with ovulatory dysfunction and resultant subfertility. Hyperprolactinemia affects the pulsatile release of GnRH, which in turn impairs the secretion of FSH and LH. It may also affect the endocrine activity
Pitale, Devdatt Laxman
core   +1 more source

Inhibiting prolactin by cabergoline accelerates mammary gland remodeling during the early dry period in dairy cows

, 2017
The inhibition of prolactin release using cabergoline, a dopamine agonist, is an effective strategy to accelerate the changes in mammary secretion composition after drying-off.
M. Boutinaud, N. Isaka, Gandemer, Eva, E. Gandemer, P. Lamberton, V. Lollivier, de Prado Taranilla, A.I., Lamberton, Philippe, Sordillo, L M, Wiart, Sandra, A. I. De Prado Taranilla, Isaka, N, Lollivier, Vanessa, Boutinaud, Marion, S. Wiart, L.M. Sordillo, De Prado Taranilla, A I   +16 more
core   +1 more source